Gilead Sciences has announced that Johanna
Johanna will assume responsibility for the company’s commercial operations effective
She joins Gilead from
“I believe that Johanna has the skills to continue to strengthen our performance and position Gilead for long-term success, building on the great talent I have seen across the organisation since joining the company several months ago,” said Daniel O’Day, chairman and chief executive officer.
He continued, “She is a talented leader with a deep understanding of the pharmaceutical industry, across therapeutic markets and geographies, as well as a proven ability to input the commercial perspective into development strategies. I look forward to welcoming her to Gilead and to working closely with her to ensure optimal commercial delivery that puts the needs of patients at the centre of all we do.”